主题：聊聊新冠，乱七八糟的瞎扯 -- 普鲁托

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

今天，美国食品药品监督管理局（Food and Drug Administration）对辉瑞公司的 Paxlovid（尼玛瑞韦片剂和利托那韦片剂，共同包装用于口服）颁发了紧急使用授权（EUA），用于治疗轻度至中度成人和儿童（12 岁及以上，体重至少 40 公斤（88磅））COVID-19患者（经由直接 SARS-CoV-2 病毒检测结果为阳性），并且有高风险发展为严重 COVID-19（包括住院或死亡）的患者。